Key result
Bofutsushosan suppresses weight gain by ~10% and reduces visceral fat in TSOD mice.
Why the study?
Visceral fat accumulation is a key risk factor for various metabolic disorders, and the preventive effects of Bofutsushosan on these conditions were investigated.
Does Bofutsushosan prevent obesity and metabolic disorders in TSOD mice?
Does Bofutsushosan prevent obesity and metabolic disorders in TSOD mice?
p-value: p=<0.01
Bofutsushosan may be effective in preventing obesity and associated metabolic disorders in a mouse model.
No takes yet. Share an insight, caveat, or question.
Bofutsushosan may attenuate visceral fat and metabolic disorders in TSOD mice; hypothesis-generating and requires clinical validation.
Shimada et al. (2008) studied Obesity and metabolic disorders. Bofutsushosan vs. Control feed was evaluated on Body weight suppression at 8 weeks (p=<0.01). Bofutsushosan significantly suppressed body weight gain by 10% and reduced visceral fat accumulation in TSOD mice compared to control.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: